Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F McDermott¹, Mahrukh A Huseni², Michael B Atkins³, Robert J Motzer⁴, Brian I Rini⁵, Bernard Escudier⁶, Lawrence Fong⁷, Richard W Joseph⁸, Sumanta K Pal⁹, James A Reeves¹⁰, Mario Sznol¹¹, John Hainsworth¹², W Kimryn Rathmell¹³, Walter M Stadler¹⁴, Thomas Hutson¹⁵, Martin E Gore¹⁶, Alain Ravaud¹⁷, Sergio Bracarda¹⁸, Cristina Suárez¹⁹, Riccardo Danielli²⁰, Viktor Gruenwald²¹, Toni K Choueiri²², Dorothee Nickles², Suchit Jhunjhunwala², Elisabeth Piault-Louis², Alpa Thobhani²³, Jiaheng Qiu², Daniel S Chen², Priti S Hegde², Christina Schiff², Gregg D Fine², Thomas Powles²⁴

Affiliations

¹ Beth Israel Deaconess Medical Center, Boston, MA, USA. dmcdermo@bidmc.harvard.edu.
² Genentech, Inc., South San Francisco, CA, USA.
³ Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
⁶ Gustave Roussy, Villejuif, France.
⁷ University of California, San Francisco School of Medicine, San Francisco, CA, USA.
⁸ Mayo Clinic Hospital -Florida, Jacksonville, FL, USA.
⁹ City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
¹⁰ Florida Cancer Specialists, Fort Myers, FL, USA.
¹¹ Yale School of Medicine, New Haven, CT, USA.
¹² Sarah Cannon Research Institute, Nashville, TN, USA.
¹³ Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁴ University of Chicago Medicine, Chicago, IL, USA.
¹⁵ Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
¹⁶ Royal Marsden Hospital, London, UK.
¹⁷ CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France.
¹⁸ Ospedale San Donato, Azienda USL Toscana Sudest, Arezzo, Italy.
¹⁹ Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
²⁰ Azienda Ospedaliera Universitaria Senese, Center for Immune-Oncology, Siena, Italy.
²¹ Medizinische Hochschule, Zentrum Innere Medizin, Abt. Hämatologie u. Onkologie, Hannover, Germany.
²² Dana-Farber Cancer Institute, Boston, MA, USA.
²³ Roche Products Ltd, Welwyn Garden City, UK.
²⁴ Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.

PMID: 30291359
DOI: 10.1038/s41591-018-0235-z

Published Erratum

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F McDermott et al. Nat Med. 2018 Dec.

. 2018 Dec;24(12):1941.

doi: 10.1038/s41591-018-0235-z.

Authors

Affiliations

¹ Beth Israel Deaconess Medical Center, Boston, MA, USA. dmcdermo@bidmc.harvard.edu.
² Genentech, Inc., South San Francisco, CA, USA.
³ Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
⁶ Gustave Roussy, Villejuif, France.
⁷ University of California, San Francisco School of Medicine, San Francisco, CA, USA.
⁸ Mayo Clinic Hospital -Florida, Jacksonville, FL, USA.
⁹ City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
¹⁰ Florida Cancer Specialists, Fort Myers, FL, USA.
¹¹ Yale School of Medicine, New Haven, CT, USA.
¹² Sarah Cannon Research Institute, Nashville, TN, USA.
¹³ Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁴ University of Chicago Medicine, Chicago, IL, USA.
¹⁵ Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
¹⁶ Royal Marsden Hospital, London, UK.
¹⁷ CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France.
¹⁸ Ospedale San Donato, Azienda USL Toscana Sudest, Arezzo, Italy.
¹⁹ Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
²⁰ Azienda Ospedaliera Universitaria Senese, Center for Immune-Oncology, Siena, Italy.
²¹ Medizinische Hochschule, Zentrum Innere Medizin, Abt. Hämatologie u. Onkologie, Hannover, Germany.
²² Dana-Farber Cancer Institute, Boston, MA, USA.
²³ Roche Products Ltd, Welwyn Garden City, UK.
²⁴ Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, UK.

PMID: 30291359
DOI: 10.1038/s41591-018-0235-z

Abstract

In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.

PubMed Disclaimer

Erratum for

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. McDermott DF, et al. Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Nat Med. 2018. PMID: 29867230 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Affiliations

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources